> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Accepts AcelRx Dsuvia Promotion Correction Plan
- URL: https://www.fdaweb.com/fda-accepts-acelrx-dsuvia-promotion-correction-plan/
- Published: 2021-06-17T12:00:00.000Z
- Updated: 2026-09-14T17:03:53.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5149561

FDA has accepted an AcelRx proposed plan to update certain promotional materials for its Dsuvia (sufentanil sublingual tablet, 30 mcg) in response to an agency 2/11 Warning Letter.

The [Warning Letter](https://www.fdaweb.com/false-or-misleading-dsuvia-claims-in-professional-promotion-opdp/) said a banner and tabletop display made false or misleading claims and representations about the drug’s risks and efficacy.

The company [says](https://ir.acelrx.com/news-releases/news-release-details/acelrx-?ref=fdaweb.com) it will provide a letter to healthcare professionals explaining corrections it has made to discontinued promotional materials. It will display the letter to professionals on the Dsuvia Web site for eight months.

“All promotional materials currently in use by AcelRx’s commercial team have been updated to address FDA’s concerns,” the company says.